Compile Data Set for Download or QSAR
Report error Found 110 Enz. Inhib. hit(s) with all data for entry = 754
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289502(US10093663, Example 27-4a)
Affinity DataIC50: 9nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159970(US9682968, Example-20a | US10093663, Example 20a)
Affinity DataIC50: 9nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 10nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159938(US9682968, Example-17-29 | US10093663, Example 17-...)
Affinity DataIC50: 11nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289488(US10093663, Example 22-2b)
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159545(US9682968, Example-17-30 | US9682968, Example-17-1...)
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289500(US10093663, Example 27-3a)
Affinity DataIC50: 14nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159486(US9682968, Example-17-11 | US10093663, Example 17-...)
Affinity DataIC50: 15nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289498(US10093663, Example 27-2a)
Affinity DataIC50: 15nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160036(US9682968, Example-21a | US10093663, Example 21a)
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289485(US10093663, Example 22-1a)
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159312(US9682968, Example-17-1 | US10093663, Example 17-1)
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160499(US9682968, Example-36 | US10093663, Example 36)
Affinity DataIC50: 20nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160500(US9682968, Example-37 | US10093663, Example 37)
Affinity DataIC50: 22nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289497(US10093663, Example 27-1b)
Affinity DataIC50: 22nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159545(US9682968, Example-17-30 | US9682968, Example-17-1...)
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159566(US9682968, Example-17-18 | US10093663, Example 17-...)
Affinity DataIC50: 27nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289450(US10093663, Example 17-5 | US10093663, Example 17-...)
Affinity DataIC50: 30nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159311(US9682968, Example-16 | US10093663, Example 16)
Affinity DataIC50: 30nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159873(US9682968, Example-17-24 | US10093663, Example 17-...)
Affinity DataIC50: 35nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159289(US9682968, Example-5-12 | US10093663, Example 5-12)
Affinity DataIC50: 37nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289451(US10093663, Example 17-3)
Affinity DataIC50: 38nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159920(US9682968, Example-17-25 | US10093663, Example 17-...)
Affinity DataIC50: 45nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160473(US9682968, Example-25a (+) | US10093663, Example 2...)
Affinity DataIC50: 47nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160506(US9682968, Example-40 | US10093663, Example 40)
Affinity DataIC50: 55nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159509(US9682968, Example-17-13 | US10093663, Example 17-...)
Affinity DataIC50: 63nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159379(US9682968, Example-17-8 | US10093663, Example 17-8)
Affinity DataIC50: 70nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289452(US10093663, Example 17-4)
Affinity DataIC50: 87nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159841(US9682968, Example-17-22 | US10093663, Example 17-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159382(US9682968, Example-17-10 | US10093663, Example 17-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289450(US10093663, Example 17-5 | US10093663, Example 17-...)
Affinity DataIC50: 120nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160501(US9682968, Example-38 | US10093663, Example 38)
Affinity DataIC50: 130nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159303(US9682968, Example-13 | US10093663, Example 13)
Affinity DataIC50: 140nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159932(US9682968, Example-17-28 | US10093663, Example 17-...)
Affinity DataIC50: 160nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289524(US10093663, Example 41 | Ethyl 4-((2S,4R)-1-((5-me...)
Affinity DataIC50: 165nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159157(US9682968, Example-5-4 | US10093663, Example 5-4)
Affinity DataIC50: 180nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159302(US9682968, Example-12 | US10093663, Example 12)
Affinity DataIC50: 230nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160508(US9682968, Example-42 | US10093663, Example 42)
Affinity DataIC50: 240nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160504(US9682968, Example-39-3 | US10093663, Example 39-3)
Affinity DataIC50: 280nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159976(US9682968, Example-20b | US10093663, Example 20b)
Affinity DataIC50: 290nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160505(US9682968, Example-39-4 | US10093663, Example 39-4)
Affinity DataIC50: 300nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160495(US9682968, Example-32-3 | US10093663, Example 32-3)
Affinity DataIC50: 340nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159506(US9682968, Example-17-12 | US10093663, Example 17-...)
Affinity DataIC50: 450nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159296(US9682968, Example-9-2 | US10093663, Example 9-2)
Affinity DataIC50: 640nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160051(US9682968, Example-21b | US10093663, Example 21b)
Affinity DataIC50: 650nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159184(US9682968, Example-5-6 | US10093663, Example 5-6)
Affinity DataIC50: 660nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159294(US9682968, Example-8 | US10093663, Example 8)
Affinity DataIC50: 710nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159102(US9682968, Example-3 | US10093663, Example 4b)
Affinity DataIC50: 720nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289501(US10093663, Example 27-3b)
Affinity DataIC50: 740nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159840(US9682968, Example-17-21 | US10093663, Example 17-...)
Affinity DataIC50: 840nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

Displayed 1 to 50 (of 110 total ) | Next | Last >>
Jump to: